Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04790682 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

LIquid Biopsy to prEdict Responses To First-line immunotherapY in Metastatic Non-small Cell LUNG Cancer. LIBERTY LUNG

Study acronym: LIBERTYLUNG
StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion date: Jun 2, 2027 to Jun 3, 2029
    • Study completion date: Jun 1, 2028 to Jun 3, 2030
    • Start date: May 27, 2021 to May 22, 2021
    • Site details revised at 1 of 3 sites
    v9
  2. Primary completion date: Oct 9, 2024 to Jun 2, 2027
    • Study completion date: Jun 1, 2026 to Jun 1, 2028
    • Secondary endpoints revised (9)
    v8
  3. Primary completion date: Jun 1, 2026 to Oct 9, 2024
    • Study completion date: Jun 1, 2027 to Jun 1, 2026
    • Start date: May 22, 2021 to May 27, 2021
    v7
  4. Primary completion date: Oct 9, 2024 to Jun 1, 2026
    • Study completion date: Jun 1, 2026 to Jun 1, 2027
    • Start date: May 27, 2021 to May 22, 2021
    v6
  5. Primary completion date: Jul 30, 2022 to Oct 9, 2024
    • Study completion date: May 1, 2024 to Jun 1, 2026
    v5
Show 3 earlier versionsHide 3 earlier versions
  1. Trial status: Not Yet Recruiting to Recruitingv4 Show 4 more changesShow less
    • Primary completion date: Jul 1, 2022 to Jul 30, 2022
    • Study completion date: Apr 1, 2024 to May 1, 2024
    • Start date changed from estimate of Apr 1, 2021 to May 27, 2021
    • Site details revised at 3 of 3 sites
  2. 2 versions Re-verified since Mar 9, 2021, no change to tracked fieldsv2-v3
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Institut Curie
43 trials monitored
See 1 trial at risk
Lung Cancer
4,790 trials monitored
See 263 trials at risk
Patient with histologically proven NSCLC in a metastatic stage, treatment naïve and eligible for first-line treatment with immune checkpoint inhibitor. Combination with chemotherapy is possible. Presence of a mutation after NGS analysis is required for ctDNA follow-up.
Trial Details
NCT Number NCT04790682
Lead Sponsor Institut Curie
Conditions
(from sponsor)		 Metastatic Lung Cancer
Related terms Lung Neoplasms
Enrollment 300 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov